Mdm2 Promotes Genetic Instability and Transformation Independent of p53
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index; 16 of the 50 sources its claims cite were checked for support.
Abstract
Mdm2, a regulator of the tumor suppressor p53, is frequently overexpressed in human malignancies. Mdm2 also has unresolved, p53-independent functions that contribute to tumorigenesis. Here, we show that increased Mdm2 expression induced chromosome/chromatid breaks and delayed DNA double-strand break repair in cells lacking p53 but not in cells with a mutant form of Nbs1, a component of the Mre11/Rad50/Nbs1 DNA repair complex. A 31-amino-acid region of Mdm2 was necessary for binding to Nbs1. Mutation of conserved amino acids in the Nbs1 binding domain of Mdm2 inhibited Mdm2-Nbs1 association and prevented Mdm2 from delaying phosphorylation of H2AX and ATM-S/TQ sites, repair of DNA breaks, and resolution of DNA damage foci. Similarly, the mutation of eight amino acids in the Mdm2 binding domain of Nbs1 inhibited Mdm2-Nbs1 interaction and blocked the ability of Mdm2 to delay DNA break repair. Both Nbs1 and ATM, but not the ubiquitin ligase activity of Mdm2, were necessary to inhibit DNA break repair. Only Mdm2 with an intact Nbs1 binding domain was able to increase the frequency of chromosome/chromatid breaks and the transformation efficiency of cells lacking p53. Therefore, the interaction of Mdm2 with Nbs1 inhibited DNA break repair, leading to chromosome instability and subsequent transformation that was independent of p53.
Overview
CoChat Summary
TL;DR
Mdm2 overexpression delays DNA double-strand break repair through an interaction with Nbs1, increasing chromosome/chromatid breaks and transformation independently of p53. This p53-independent oncogenic function requires an intact Mdm2-Nbs1 binding interface and ATM, but not Mdm2’s ubiquitin ligase activity.
Key findings
- Mdm2 overexpression increased chromosome/chromatid breaks independent of ARF and p53: in NIH 3T3 cells, vector control had 36/1,400 metaphases with breaks (2.6%) versus 75/1,275 (5.9%) with Mdm2 (P = 0.00004); in p53−/− MEFs, vector had 38/1,508 (2.5%) versus 84/1,529 (5.5%) with Mdm2 (P = 0.00006).
- Mdm2 required Nbs1 for this effect: Mdm2 overexpression did not increase DNA breaks in Nbs1ΔB/ΔB MEFs, and Mdm2 mutants with seven or nine point mutations in its Nbs1 binding domain failed to delay DNA break repair or increase breaks.
- The Mdm2-Nbs1 interaction mapped to a 31-amino-acid region of Mdm2 (aa 198–228) and aa 474–512 of Nbs1; eight point mutations in Nbs1’s Mdm2 binding domain severely reduced Mdm2 association and blocked Mdm2-mediated repair delay.
- Mdm2 delayed early DNA damage signaling and repair, reducing γ-H2AX and phospho-ATM-S/TQ foci shortly after irradiation and prolonging DNA damage foci; this required Nbs1 and ATM but not Mdm2’s E3 ubiquitin ligase activity, and only Mdm2 with an intact Nbs1 binding domain increased transformation efficiency of p53−/− MEFs in soft agar.
Methods
- Used 293T, NIH 3T3, p53−/−, ARF−/−, wild-type, ATM−/− ARF−/−, and SV40-transformed Nbs1+/+ or Nbs1ΔB/ΔB MEFs; retroviral MSCV-IRES-GFP/YFP vectors expressed wild-type or mutant Mdm2 and Nbs1 constructs.
- Measured protein interactions by immunoprecipitation/Western blot; genomic instability by blind metaphase chromosome break analysis; DNA double-strand breaks by neutral comet assay after 5 Gy gamma irradiation; damage foci by immunofluorescence for γ-H2AX, phospho-ATM, and Nbs1; checkpoints by radioresistant DNA synthesis and G2/M assays; transformation by soft agar colony formation in p53−/− MEFs.
- Metaphase break comparisons used Fisher’s exact test; comet tail moment was calculated by CometScore; foci were quantified for at least 50 cells per sample per interval per experiment, with experiments performed a minimum of three times.
Limitations
- Stated: the assays used to measure S and G2/M checkpoints may not be sensitive enough to detect small differences; exactly how Mdm2 inhibits the early DNA damage response through Nbs1 remains future work, and other explanations are possible.
- Stated: mutation of the Nbs1 binding domain did not completely abolish Mdm2-Nbs1 association, so Mdm2 with nine point mutations still produced slightly more colonies than vector control.
- Evident from the text: most mechanistic conclusions rely on overexpression in cultured MEFs/3T3 cells, and transformation was tested only in p53−/− MEFs, with no in vivo tumor data reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 Valid · 0 Not valid · 16 Not checked · 109 Own results and interpretations
Every source the paper cites for this claim was checked and supports it.
In the paper
“Recently, we discovered the interaction between Mdm2 and Nbs1”
What the sources say
- Supportedcites [1] matched to “Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair” (2005) source
In the section describing the Nbs1–Mdm2 interaction (Fig. 6), the paper reports that Nbs1 bound specifically to GST-Mdm2 and concludes that the interaction was specific and appears direct. This supports the attributed claim that Mdm2 binds to Nbs1. (LLM, conf=0.95)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“a third of the lymphomas arising in Eμ-myc transgenic mice that have mutated p53 or lack p53 also overexpress Mdm2 (2, 15)”
What the sources say
- Partly supportedcites [2] Alt J. R., 2003, EMBO J. sourceExperimental — accuracy not yet measured
In “The effects of Mdm2 haplo-insufficiency are p53 dependent” (page unavailable), the paper reports Mdm2 overexpression in many lymphomas with mutated p53. It does not give a one-third figure for lymphomas with mutated or deleted p53 that also overexpress Mdm2; the percentages it reports use all analyzed lymphomas as the denominator. (LLM, conf=0.84)
- Supportedcites [15] matched to “Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis” (1999) source
The Results report six Eµ-myc lymphomas with mutant p53 and one with deleted p53, and identify Mdm2 overexpression in two of those tumors. Two of seven is approximately a third. The indexed passages have no page numbers. (LLM, conf=0.92)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“mammary-specific-Mdm2-transgenic mice exhibit increased ploidy, a marker of genome instability, in mammary epithelial cells regardless of p53 expression (27).”
What the sources say
- Supportedcites [27] matched to “Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53.” (1997) source
The Discussion reports increased polyploidy in MDM2-overexpressing mammary epithelial cells in both wild-type and p53-null mice. The cell-cycle analysis likewise reports polyploid nuclei in the transgenic glands and concludes that the effect is independent of p53. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Initial data from neutral comet assays, which measure DNA double-strand breaks on a single-cell basis and reflect the amount of DNA damage present (36), indicated that overexpression of Mdm2 inhibited DNA double-strand break repair independent of its N or C terminus (1).”
What the sources say
- Supportedcites [1] matched to “Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair” (2005) source
The neutral comet-assay results (Fig. 8; page unavailable) show that overexpressed Mdm2 delayed double-strand break repair. The same results report that an Mdm2 fragment comprising residues 198–400, which lacks both termini, delayed repair similarly to full-length Mdm2. (LLM, conf=0.91)
hedgedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Previously, we reported that a region of the central domain of Mdm2 (aa 198 to 314) was necessary for Mdm2 to associate with Nbs1 (1).”
What the sources say
- Supportedcites [1] matched to “Mdm2 Binds to Nbs1 at Sites of DNA Damage and Regulates Double Strand Break Repair” (2005) source
In “Amino Acids 198–314 of Mdm2,” the authors report that the Mdm2 198–314 mutant co-immunoprecipitated the Mre11–Nbs1–Rad50 complex, whereas mutants lacking the relevant region did not. They conclude that the minimal essential domain for association lies within amino acids 198–314; the paper also identifies Nbs1 as the mediator of Mdm2’s association with the complex. (LLM, conf=0.94)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
99 more claims · 2 with their cited sources checked
Create a free account to see all 140 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 17
- It may state two separate claims as one. 25
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been previously demonstrated that Mdm2 binds directly to Nbs1 of the Mre11/Rad50/Nbs1 (MRN) complex, co-localizes with Nbs1 to DNA damage foci, and inhibits the DNA damage response (24, 25).”
From Potentiation of carboplatin-mediated DNA damage by the Mdm2 modulator Nutlin-3a in a humanized orthotopic breast-to-lung metastatic model (2015) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“DNA break repair is already delayed in the Nbs1ΔB/ΔB MEFs and addition of Nutlin did not further inhibit DNA repair (Figure 1E).”
From Pharmacologically increasing Mdm2 Inhibits DNA repair and cooperates with genotoxic agents to kill p53-inactivated ovarian cancer cells (2015) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“normal physiological levels of Mdm2 were shown to regulate Nbs1-mediated DNA break repair”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Bouska, et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated levels of Mdm2 result in increased chromatid and chromosome breaks as well as fusions”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Bouska, et al., 2008
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“This also led to Mdm2-directed cellular transformation not dependent on p53.”
From Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis (2012) · cites this paper as [32]
21 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“Over 3,000 individual metaphase cells from four independent experiments with GFP+ NIH 3T3 cells were evaluated.”
§ RESULTS
“Total d 22/1,225 (1.8) 36/1,400 (2.6) 75/1,275 (5.9)”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ RESULTS
“Over 4,000 individual metaphase cells from six independent experiments with GFP+ p53−/− MEFs were analyzed.”
§ RESULTS
“Total e 11/1,426 (0.8) 38/1,508 (2.5) 84/1,529 (5.5)”
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation
Bakkenist, C. J., & Kastan, M. B. (2003) · Nature · doi:10.1038/nature01368 · Cited by 3,466 · cited 3×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodRegulation of p53 stability by Mdm2
Kubbutat, M. H. G., Jones, S. N., & Vousden, K. H. (1997) · Nature · doi:10.1038/387299a0 · Cited by 3,312 · cited 2×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodMomand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113 · cited 2×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodATM and ATR Substrate Analysis Reveals Extensive Protein Networks Responsive to DNA Damage
Matsuoka, S., Ballif, B. A., Smogorzewska, A., McDonald, E. R., Hurov, K. E., Luo, J., Bakalarski, C. E., Zhao, Z., Solimini, N., Lerenthal, Y., et al. (2007) · Science · doi:10.1126/science.1140321 · Cited by 3,075
DNA double-strand breaks: signaling, repair and the cancer connection
Khanna, K. K., & Jackson, S. P. (2001) · Nature Genetics · doi:10.1038/85798 · Cited by 2,455
Megabase Chromatin Domains Involved in DNA Double-Strand Breaks in Vivo
Rogakou, E. P., Boon, C., Redon, C., & Bonner, W. M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.5.905 · Cited by 2,422
ATM Phosphorylates Histone H2AX in Response to DNA Double-strand Breaks
Burma, S., Chen, B. P., Murphy, M., Kurimasa, A., & Chen, D. J. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c100466200 · Cited by 1,954 · cited 4×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodInfluentialOncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53
Honda, R., Tanaka, H., & Yasuda, H. (1997) · FEBS Letters · doi:10.1016/s0014-5793(97)01480-4 · Cited by 1,951 · cited 2×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethodATM Activation by DNA Double-Strand Breaks Through the Mre11-Rad50-Nbs1 Complex
Lee, J.-H., & Paull, T. T. (2005) · Science · doi:10.1126/science.1108297 · Cited by 1,424 · cited 2×
“ing of amino acids (aa) 1 to 228 (1-228) was generated by PCR and Mdm2”
BackgroundMethod
Research works printed but not linked: 3
- Cordon-Cardo C., 1994, Cancer Res., 54, 794
- Ganguli G., 2003, Mol. Cancer Res., 1, 1027
- Lu M. L., 2002, Clin. Cancer Res., 8, 171
Cited by
MDM2, MDMX and p53 in oncogenesis and cancer therapy
Wade, M., Li, Y.-C., & Wahl, G. M. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3430 · Cited by 1,279
The MDM2-p53 pathway revisited
Subhasree, N., Jiangjiang, Q., Kalkunte, S., Minghai, W., & Ruiwen, Z. (2013) · The Journal of Biomedical Research · doi:10.7555/jbr.27.20130030 · Cited by 414
Mdm2-mediated ubiquitylation: p53 and beyond
Marine, J.-C., & Lozano, G. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2009.68 · Cited by 354
Zhang, J., Sun, Q., Zhang, Z., Ge, S., Han, Z.-G., & Chen, W.-T. (2013) · Oncogene · doi:10.1038/onc.2012.28 · Cited by 224
Eischen, C. M. (2016) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026096 · Cited by 161
Self-citationProteasome system of protein degradation and processing
Sorokin, A. V., Kim, E. R., & Ovchinnikov, L. P. (2009) · Biochemistry (Moscow) · doi:10.1134/s000629790913001x · Cited by 156
Drug Development Targeting the Ubiquitin–Proteasome System (UPS) for the Treatment of Human Cancers
Zhang, X., Linder, S. T., & Bazzaro, M. (2020) · Cancers · doi:10.3390/cancers12040902 · Cited by 157
Adams, C. M., Mitra, R., Xiao, Y., Michener, P., Palazzo, J., Chao, A., Gour, J., Cassel, J., Salvino, J. M., & Eischen, C. M. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-1131 · Cited by 117
Self-citationp53-Independent Effects of Mdm2
Bohlman, S., & Manfredi, J. J. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_13 · Cited by 103
p53 Activity Results in DNA Replication Fork Processivity
Klusmann, I., Rodewald, S., Müller, L., Friedrich, M., Wienken, M., Li, Y., Schulz‐Heddergott, R., & Dobbelstein, M. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.10.036 · Cited by 86
Wang, W., Qin, J., Voruganti, S., Wang, M., Sharma, H., Patil, S. A., Zhou, J., Wang, H., Mukhopadhyay, D., Buolamwini, J. K., et al. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.001 · Cited by 90
The Mdm network and its regulation of p53 activities: a rheostat of cancer risk
Eischen, C. M., & Lozano, G. (2014) · Human Mutation · doi:10.1002/humu.22524 · Cited by 79
Self-citationmiR-339-5p regulates the p53 tumor-suppressor pathway by targeting MDM2
Jansson, M., Damas, N. D., Lees, M. J., Jacobsen, A., & Lund, A. H. (2014) · Oncogene · doi:10.1038/onc.2014.130 · Cited by 81
DNA damage response to the Mdm2 inhibitor Nutlin-3
Verma, R., Rigatti, M. J., Belinsky, G. S., Godman, C. A., & Giardina, C. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.09.020 · Cited by 76
Mdm2 affects genome stability independent of p53
Bouska, A., & Eischen, C. M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3732 · Cited by 71
“transformation of p53-null MEFs, and again, an intact Nbs1-binding domain in Mdm2 was required for the increased transformation potential of Mdm2 (19).”
BackgroundResultSelf-citationMdmx promotes genomic instability independent of p53 and Mdm2
Carrillo, A. M., Bouska, A., Arrate, M. P., & Eischen, C. M. (2015) · Oncogene · doi:10.1038/onc.2014.27 · Cited by 69
Self-citationHároníková, L., Bonczek, O., Zatloukalová, P., Kokas, F. Z., Kucerikova, M., Coates, P. J., Fåhræus, R., & Vojtěšek, B. (2021) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-021-00293-6 · Cited by 76
Murine double minute 2: p53-independent roads lead to genome instability or death
Bouska, A. C., & Eischen, C. M. (2009) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2009.02.006 · Cited by 72
Self-citationChromatin modifiers Mdm2 and RNF2 prevent RNA:DNA hybrids that impair DNA replication
Klusmann, I., Wohlberedt, K., Magerhans, A., Teloni, F., Korbel, J. O., Altmeyer, M., & Dobbelstein, M. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1809592115 · Cited by 69
Xiong, H., Liao, Z. X., Liu, Z., et al. (2012) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2012.09.024 · Cited by 63
Tolerance of Chromosomal Instability in Cancer: Mechanisms and Therapeutic Opportunities
Gronroos, E. C., & López-García, C. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1958 · Cited by 71
Urso, L., Calabrese, F., Favaretto, A. G., Conte, P., & Pasello, G. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.08.019 · Cited by 64
MTBP suppresses cell migration and filopodia formation by inhibiting ACTN4
Agarwal, N. A., Adhikari, A. S., Iyer, S. V., et al. (2012) · Oncogene · doi:10.1038/onc.2012.69 · Cited by 60
Udayakumar, T. S., Shareef, M. M., Diaz, D. A., Ahmed, M. M., & Pollack, A. S. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.05.007 · Cited by 69
SOX1 down-regulates β-catenin and reverses malignant phenotype in nasopharyngeal carcinoma
Guan, Z., Zhang, J., Wang, J., Wang, H., Zheng, F.-M., Peng, J., Xu, Y., Yan, M., Liu, B., Cui, B., et al. (2014) · Molecular Cancer · doi:10.1186/1476-4598-13-257 · Cited by 60
KMT Set7/9 affects genotoxic stress response via the Mdm2 axis
Lezina, L., Aksenova, V., Fedorova, O., Kriger, D. V., Shuvalov, O. Y., Antonov, A. V., Tentler, D., Garabadgiu, A. V., Melino, G., & Barlev, N. A. (2015) · Oncotarget · doi:10.18632/oncotarget.4584 · Cited by 59
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis
Wan, Y., Wu, W., Yin, Z., Guan, P., & Zhou, B. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-208 · Cited by 61
Role of Mdm2 and Mdmx in DNA repair
Eischen, C. M. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjw052 · Cited by 45
Self-citationWang, J., Huang, Y., Guan, Z., Zhang, J.-L., Su, H.-K., Zhang, W., Yue, C.-F., Yan, M., Guan, S., & Liu, Q. Q. (2014) · Oncotarget · doi:10.18632/oncotarget.2149 · Cited by 47
Oncogenic Protein MTBP Interacts with MYC to Promote Tumorigenesis
Grieb, B. C., Gramling, M., Arrate, M. P., Chen, X., Beauparlant, S. L., Haines, D. S., Xiao, H., & Eischen, C. M. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2149 · Cited by 43
Self-citationPalliyage, G. H., Singh, S., Ashby, C. R., Tiwari, A. K., & Chauhan, H. (2019) · AAPS PharmSciTech · doi:10.1208/s12249-019-1457-1 · Cited by 44
Tonsing-Carter, E., Bailey, B. J., Saadatzadeh, M. R., Ding, J., Wang, H., Sinn, A. L., Peterman, K. M., Spragins, T. K., Silver, J. M., Sprouse, A. A., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0237 · Cited by 42
Self-citationAging mice have increased chromosome instability that is exacerbated by elevated Mdm2 expression
Lushnikova, T., Bouska, A., Odvody, J., Dupont, W. D., & Eischen, C. M. (2011) · Oncogene · doi:10.1038/onc.2011.172 · Cited by 40
Self-citationChen, J., Xu, D., Cao, J., Zuo, L., Han, Z., Tian, Y., Chu, C., Wang, Z., Pan, X., & Cui, X. (2021) · Cancer Cell International · doi:10.1186/s12935-021-01831-0 · Cited by 46
The Role of MDM2 in Promoting Genome Stability versus Instability
Saadatzadeh, M., Elmi, A., Pandya, P., Bijangi-Vishehsaraei, K., Ding, J., Stamatkin, C., Cohen-Gadol, A., & Pollok, K. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18102216 · Cited by 41
Yu, Z.-C., Huang, Y., & Shieh, S.-Y. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1173 · Cited by 50
Structural basis for DNA damage-induced phosphoregulation of MDM2 RING domain
Magnussen, H. M., Ahmed, S. F., Sibbet, G. J., Hristova, V. A., Nomura, K., Hock, A. K., Archibald, L. J., Jamieson, A. G., Fushman, D., Vousden, K. H., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15783-y · Cited by 38
GPRC5A deficiency leads to dysregulated MDM2 via activated EGFR signaling for lung tumor development
Song, H., Sun, B., Liao, Y., Xu, D., Guo, W., Wang, T., Jing, B., Hu, M., Li, K., Yao, F., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31726 · Cited by 37
Li, W., Peng, X., Lang, J., & Xu, C. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00631 · Cited by 39
MTBP Is Overexpressed in Triple-Negative Breast Cancer and Contributes to Its Growth and Survival
Grieb, B. C., Chen, X., & Eischen, C. M. (2014) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0069 · Cited by 40
Self-citationSmarcal1 and Zranb3 Protect Replication Forks from Myc-Induced DNA Replication Stress
Puccetti, M. V., Adams, C. M., Kushinsky, S., & Eischen, C. M. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-2705 · Cited by 36
Self-citationPold3is required for genomic stability and telomere integrity in embryonic stem cells and meiosis
Zhou, Z., Wang, L., Ge, F., Gong, P., Wang, H., Wang, F., Chen, L., & Liu, L. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky098 · Cited by 36
Carrillo, A. M., Hicks, M., Khabele, D., & Eischen, C. M. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-15-0089 · Cited by 31
Self-citationOkoro, D. R., Arva, N. C., Gao, C., Polotskaia, A., Puente, C., Rosso, M., & Bargonetti, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0077643 · Cited by 36
MDM2 and MDM4 splicing: an integral part of the cancer spliceome
Jeyaraj, S. C., O’Brien, D. M., & Chandler, D. S. (2009) · Frontiers in bioscience · doi:10.2741/3402 · Cited by 37
He, T., Guo, J., Song, H., Zhu, H., Di, X., Min, H., Wang, Y., Chen, G., Dai, W., Ma, J., et al. (2017) · Pathology & Oncology Research · doi:10.1007/s12253-017-0215-5 · Cited by 30
Conradt, L., Henrich, A., Wirth, M., Reichert, M., Lesina, M., Algül, H., Schmid, R. M., Krämer, O. H., Saur, D., & Schneider, G. (2013) · International Journal of Cancer · doi:10.1002/ijc.27916 · Cited by 30
“Direct interaction of Nbs1 with Mdm2 was demonstrated.(28,30) Interestingly, overexpression of Mdm2 leads to a delay in DSB repair independent of p53 and the E3 ubiquitin ligase activity of Mdm2, but strictly dependent on Nbs1.”
BackgroundWang, W., Qin, J., Li, X., Tao, G., Wang, Q., Wu, X., Zhou, J., Zi, X., & Zhang, R. (2018) · Carcinogenesis · doi:10.1093/carcin/bgy063 · Cited by 32
Functional role of RRS 1 in breast cancer cell proliferation
Song, J., Ma, Z., Hua, Y., Xu, J., Li, N., Ju, C., & Hou, L. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13922 · Cited by 31
Hayashida, K., Kajino, K., Hattori, M., Wallace, M., Morrison, I. W., Greene, M. I., & Sugimoto, C. (2012) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2012.08.008 · Cited by 30
Zhao, Y., Tan, M., Liu, X., Xiong, X., & Sun, Y. (2018) · Cell Death and Disease · doi:10.1038/s41419-017-0192-3 · Cited by 28
Mdm4 supports DNA replication in a p53-independent fashion
Wohlberedt, K., Klusmann, I., Derevyanko, P. K., Henningsen, K. M., Choo, J. A. M. Y., Manzini, V., Magerhans, A., Giansanti, C., Eischen, C. M., Jochemsen, A. G., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1325-1 · Cited by 27
Self-citationStress-Induced Alternative Splice Forms of MDM2 and MDMX Modulate the p53-Pathway in Distinct Ways
Jacob, A. G., Singh, R. K., Comiskey, D. F., Rouhier, M. F., Mohammad, F., Bebee, T. W., & Chandler, D. S. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104444 · Cited by 25
Using Mouse Models to Explore MDM-p53 Signaling in Development, Cell Growth, and Tumorigenesis
Gannon, H., & Jones, S. N. (2012) · Genes & Cancer · doi:10.1177/1947601912455324 · Cited by 27
Zeng, Y., Fu, M., Wu, G.-W., Zhang, A.-Z., Chen, J., Lin, H., Fu, Y., Jia, J., Cai, Z., Wu, X., et al. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3642 · Cited by 25
Shinohara, A., Sakano, S., Hinoda, Y., Nishijima, J., Kawai, Y., Misumi, T., Nagao, K., Hara, T., & Matsuyama, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01331.x · Cited by 30
MDM2 binding protein, a novel metastasis suppressor
Iwakuma, T., & Agarwal, N. A. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9364-x · Cited by 24
Role of E3 ubiquitin ligases in gastric cancer
Hou, Y., & Deng, J. (2015) · World Journal of Gastroenterology · doi:10.3748/wjg.v21.i3.786 · Cited by 22
Protecting the genome from mdm2 and mdmx
Melo, A. N., & Eischen, C. M. (2012) · Genes & Cancer · doi:10.1177/1947601912454139 · Cited by 20
Self-citationDefective replication stress response inhibits lymphomagenesis and impairs lymphocyte reconstitution
Puccetti, M. V., Fischer, M. A., Arrate, M. P., Boyd, K. L., Duszynski, R. J., Betous, R., Cortez, D., & Eischen, C. M. (2016) · Oncogene · doi:10.1038/onc.2016.408 · Cited by 19
Self-citationRiley, M. F., You, M. J., Multani, A. S., & Lozano, G. (2015) · Oncogene · doi:10.1038/onc.2015.88 · Cited by 20
Liu, W., He, L., Ramírez, J., & Ratain, M. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0890 · Cited by 21
Senturk, J. C., Bohlman, S., & Manfredi, J. J. (2017) · Oncogene · doi:10.1038/onc.2017.229 · Cited by 22
MDM2 Overexpression, Activation of Signaling Networks, and Cell Proliferation
Deb, S. P., Singh, S., & Deb, S. (2014) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-94-017-9211-0_12 · Cited by 20
What do we need to know and understand about p53 to improve its clinical value?
Salomao, N., Karakostis, K., Hupp, T., Vollrath, F., Vojtesek, B., & Fahraeus, R. (2021) · The Journal of Pathology · doi:10.1002/path.5677 · Cited by 15
“Increased MDM2 levels reduced MRN activity, ATM kinase signalling, and DNA break repair, thus indicating a suppressive function that can enhance cell transformation in p53-null cells [78].”
BackgroundA novel mouse model of rhabdomyosarcoma underscores the dichotomy of MDM2-ALT1 function in vivo
Comiskey, D. F., Jacob, A. G., Sanford, B. L., Montes, M., Goodwin, A., Steiner, H. E., Matsa, E., Tapia-Santos, A. S., Bebee, T. W., Grieves, J. L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.282 · Cited by 16
Regulation of kidney development by the Mdm2/Mdm4–p53 axis
El-Dahr, S. S., Hilliard, S. A., & Saifudeen, Z. R. (2017) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjx005 · Cited by 15
Matijašević, Z., Krzywicka-Racka, A., Sluder, G., Gallant, J., & Jones, S. N. (2016) · Oncogenesis · doi:10.1038/oncsis.2016.62 · Cited by 14
Kaderi, M. A., Mansouri, M. R., Zainuddin, N., Cahill, N., Gunnarsson, R., Jansson, M., Kimby, E. K., Åleskog, A., Lundin, J., Glimelius, B., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.06.006 · Cited by 13
MDM2 Implications for Potential Molecular Pathogenic Therapies of Soft-Tissue Tumors
Sun, S. Y. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12113638 · Cited by 14
Murine double minute 2, a potential p53-independent regulator of liver cancer metastasis
Ranjan, A., Bera, K., & Iwakuma, T. (2016) · Hepatoma Research · doi:10.20517/2394-5079.2015.67 · Cited by 12
Wang, W., Nijampatnam, B., Velu, S. E., & Zhang, R. (2016) · Frontiers of Chemical Science and Engineering · doi:10.1007/s11705-016-1562-6 · Cited by 11
MDM2 SNP309 is an ethnicity-dependent risk factor for digestive tract cancers
Chen, B., Cao, L., Hu, K., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-1453-0 · Cited by 11
Fan, Y., Zhang, W., Ni, A., Mahato, B., & Chavala, S. H. (2018) · American Journal Of Pathology · doi:10.1016/j.ajpath.2018.05.017 · Cited by 10
Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis
Lehman, J., & Mayo, L. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms131216373 · Cited by 9
MDM2 SNP309 polymorphism is associated with lung cancer risk in women: A meta-analysis using METAGEN
He, W., Long, J., Xian, L., Pang, F., Su, L., WEI, S., Wei, B., & Hu, Y. (2012) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2012.640 · Cited by 10
Herok, M., Wawrzynów, B., Maluszek, M. J., Olszewski, M. B., Żylicz, M., & Żylicz, M. (2021) · Cancers · doi:10.3390/cancers13184501 · Cited by 5
The 40bp indel polymorphism of MDM2 increase the risk of cancer: An updated meta-analysis.
Moazeni‐Roodi, A., Ghavami, S., & Hashemi, M. M. (2019) · PubMed · doi:10.22099/mbrc.2019.31527.1364 · Cited by 6
The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-∆5 in Breast Cancer Cells
Huun, J., Gansmo, L. B., Mannsåker, B., Iversen, G. T., Sommerfelt-Pettersen, J. K., Øvrebø, J. I., Lønning, P. E., & Knappskog, S. (2017) · Translational Oncology · doi:10.1016/j.tranon.2017.07.006 · Cited by 7
Chen, B., Xiong, M., & Meng, X.-L. (2014) · Diseases of the Esophagus · doi:10.1111/dote.12240 · Cited by 6
Adenovirus Ad-p53AIP1-mediated gene therapy and its regulation of p53-MDM2 interactions
Jiang, Y., Chen, H., Jia, H., Xu, Y., LIU, G., Wang, Y., Yang, X., & Lu, Y. (2010) · Experimental and Therapeutic Medicine · doi:10.3892/etm_00000057 · Cited by 6
Siriki, A., Ragland, G., Vasireddy, J., & Chitneni, S. K. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130394 · Cited by 8
Therapeutic considerations for Mdm2: not just a one trick pony
Lehman, J. A., Eitel, J. A., Batuello, C. N., & Mayo, L. D. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.11.1309 · Cited by 12
Yadav, R. P., Ghatak, S., Chakraborty, P., Lalrohlui, F., Kannan, R., Kumar, R., Pautu, J. L., Zomingthanga, J., Chenkual, S., Muthukumaran, R. B., et al. (2018) · Environmental Science and Pollution Research · doi:10.1007/s11356-018-3080-1 · Cited by 4
p53 E3 ubiquitin protein ligase homolog regulates p53 in vivo in the adult mouse eye lens.
Jaramillo‐Rangel, G., Ortega‐Martínez, M., Sepúlveda‐Saavedra, J., Cárdenas, O. S., & Montes‐de‐Oca‐Luna, R. (2013) · PubMed Central · Cited by 6
The Role of Nuclear Phosphoinositides in the p53-MDM2 Nexus
Lee, J. H., Salah, M. K., Chen, X., Kucherenko, N. V., Cryns, V. L., & Anderson, R. A. (2025) · Cells · doi:10.3390/cells14151126 · Cited by 6
Chen, C., He, X., Chen, M., Du, T., Qin, W., Jing, W., & Zhang, H. (2023) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-023-03530-9 · Cited by 3
Guerra, J. L. L., Song, Y., Nguyen, Q., et al. (2018) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2018.02.006 · Cited by 3
Li, Y., Xu, L., Lu, X., Fu, B., Jiang, Q., Xiong, W., Tang, W., & Wu, D. (2025) · Digestive Diseases and Sciences · doi:10.1007/s10620-025-09576-w · Cited by 3
Chen, J., Xu, D., Cao, J., et al. (2020) · Research Square · doi:10.21203/rs.3.rs-120257/v1 · Cited by 2
Jalving, T., Dufau, C., Nieto, J. S., Altimari, D. M. D., Veen, S. E. V. H.-V., Jin, E. H.-M., Visser, N. L., van Boven, H. H., van der Graaf, W. T. A., van Houdt, W. J., et al. (2026) · Cancer Research · doi:10.1158/0008-5472.can-25-1858 · Cited by 2
Nutraceuticals in Preventive Oncology: Chemical Biology and Translational Pharmaceutical Science
Zhang, R., & Nag, S. A. (2014) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-319-06151-1_16 · Cited by 1
ZNF121 recruits YTHDF2 to modulate mRNA stabilityPreprint
Burke, G. L., Nabeel‐Shah, S., Pu, S., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.18.706452
Liu, W., He, L., Ramírez, J., & Ratain, M. J. (2023) · doi:10.1158/1078-0432.c.6517734
Non-canonical functions of the MDM2 oncoprotein
Manzini, V. (2022) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9537
Shuvalov, O. Y., Petukhov, A., Fedorova, O., Daks, A. A., & Barlev, N. A. (2018) · Tsitologiya · doi:10.7868/s0041377118100089
The tumour suppressor p53 as a supporter of DNA replication
Klusmann, I. (2018) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-7143
Modulation of the Mdm2 signaling axis sensitizes triple-negative breast cancer cells to carboplatin
Tonsing-Carter, E. Y. (2014) · IUScholarWorks (Indiana University) · doi:10.7912/c2/308
Metadata
- Authors
- Bouska, A., Lushnikova, T., Plaza, S., & Eischen, C. M.
- Affiliations
- University of Nebraska Medical Center (US)
- Vanderbilt University (US)
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2008-08-01
- Volume
- 28
- Issue
- 15
- Pages
- 4862-4874
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2493369
- OpenAlex
- W2139466852
- Cited by
- 105
- References
- 55
- Citations by year
- 2026: 2 · 2025: 3 · 2023: 5 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2018: 12 · 2017: 6 · 2016: 8 · 2015: 7 · 2014: 16 · 2013: 5 · 2012: 11
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- journals.asm.org/non-commercial-tdm-license (tdm)
- Locations
- Molecular and Cellular Biology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (R01CA117935, CA098139, CA117935, R01CA098139)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Keywords
- MDM2, NBS1, p53-independent function, DNA double-strand break repair, chromosomal instability, transformation, Mre11-Rad50-Nbs1 complex, ATM, H2AX phosphorylation, DNA damage foci, chromosomal breaks
- MeSH terms
- Amino Acid Sequence, Animals, Cell Transformation, Neoplastic, DNA Repair, DNA-Binding Proteins, Humans, Molecular Sequence Data, Mutation, Nuclear Proteins, Protein Binding, Structure-Activity Relationship, Tumor Suppressor Protein p53, Protein Serine-Threonine Kinases, Protein Structure, Tertiary, Cell Cycle Proteins, Tumor Suppressor Proteins, NIH 3T3 Cells, Genomic Instability, Mice, Proto-Oncogene Proteins c-mdm2, Ataxia Telangiectasia Mutated Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.